Cross-topic event
Life Biosciences Doses First Patient in Global First Cellular Reprogramming Trial ER-100 for Glaucoma and NAION
Jun 21, 20262 reports
Jun 21, 2026
Sciencedesk view
Life Biosciences Doses First Patient in Global First Cellular Reprogramming Trial ER-100 for Glaucoma and NAION
Per Times Now on June 21, 2026, Boston-based Life Biosciences has dosed the first patient in ER-100, the world's first cellular reprogramming therapy to enter h…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
ER-100 cellular reprogramming: first-in-human "reverse-ageing" trial underway
Per Times Now on June 21, Boston-based Life Biosciences' ER-100 is in Phase 1 — the first human test of cellular reprogramming via OSK transcription factors. Th…
READ THE DAY'S DIGEST →